Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

10.44USD
3:59pm EST
Change (% chg)

$-0.18 (-1.69%)
Prev Close
$10.62
Open
$10.65
Day's High
$10.66
Day's Low
$10.22
Volume
576,031
Avg. Vol
405,213
52-wk High
$10.84
52-wk Low
$3.80

PGNX.OQ

Chart for PGNX.OQ

About

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their... (more)

Overall

Beta: 3.20
Market Cap(Mil.): $743.95
Shares Outstanding(Mil.): 70.05
Dividend: --
Yield (%): --

Financials

  PGNX.OQ Industry Sector
P/E (TTM): 67.99 47.00 29.32
EPS (TTM): 0.16 -- --
ROI: 8.00 -4.07 13.03
ROE: 10.47 4.71 14.17

BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment

* Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald

* Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing

* Progenics Pharmaceuticals Inc - files for mixed shelf of up to $250 million - SEC filing Source text: (http://bit.ly/2jcUEzy) Further company coverage:

Jan 06 2017

BRIEF-Progenics announces $50 million RELISTOR royalty-backed financing

* Progenics announces $50 million RELISTOR royalty-backed financing

Nov 07 2016

BRIEF-Valeant and Progenics announce the U.S. commercial launch of FDA-approved Relistor tablets

* Valeant and Progenics announce the U.S. commercial launch of FDA approved Relistor tablets Source text for Eikon: Further company coverage:

Sep 06 2016

Progenics Pharmaceuticals whistleblower wins another $3 million

A former Progenics Pharmaceuticals Inc chemist who last year won a $1.66 million verdict from a biotechnology company accused of retaliating against him for whistleblower claims was awarded at least $3.3 million more on Tuesday.

Aug 30 2016

More From Around the Web

Earnings vs. Estimates